174 related articles for article (PubMed ID: 38201436)
1. KLC1-ROS1 Fusion Exerts Oncogenic Properties of Glioma Cells via Specific Activation of JAK-STAT Pathway.
Fujii T; Nakano Y; Hagita D; Onishi N; Endo A; Nakagawa M; Yoshiura T; Otsuka Y; Takeuchi S; Suzuki M; Shimizu Y; Toyooka T; Matsushita Y; Hibiya Y; Tomura S; Kondo A; Wada K; Ichimura K; Tomiyama A
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201436
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel KLC1-ROS1 fusion in a case of pediatric low-grade localized glioma.
Nakano Y; Tomiyama A; Kohno T; Yoshida A; Yamasaki K; Ozawa T; Fukuoka K; Fukushima H; Inoue T; Hara J; Sakamoto H; Ichimura K
Brain Tumor Pathol; 2019 Jan; 36(1):14-19. PubMed ID: 30350109
[TBL] [Abstract][Full Text] [Related]
3. Novel
Deland L; Keane S; Bontell TO; Fagman H; Sjögren H; Lind AE; Carén H; Tisell M; Nilsson JA; Ejeskär K; Sabel M; Abel F
Cancer Genomics Proteomics; 2022; 19(6):711-726. PubMed ID: 36316040
[TBL] [Abstract][Full Text] [Related]
4. Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.
Neel DS; Allegakoen DV; Olivas V; Mayekar MK; Hemmati G; Chatterjee N; Blakely CM; McCoach CE; Rotow JK; Le A; Karachaliou N; Rosell R; Riess JW; Nichols R; Doebele RC; Bivona TG
Cancer Res; 2019 Feb; 79(3):546-556. PubMed ID: 30538120
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma.
Suehara Y; Kohsaka S; Hayashi T; Akaike K; Kurisaki-Arakawa A; Sato S; Kobayashi E; Mizuno S; Ueno T; Morii T; Okuma T; Kurihara T; Hasegawa N; Sano K; Sasa K; Okubo T; Kim Y; Mano H; Saito T
Clin Orthop Relat Res; 2021 Apr; 479(4):838-852. PubMed ID: 33196586
[TBL] [Abstract][Full Text] [Related]
6. Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.
Davare MA; Henderson JJ; Agarwal A; Wagner JP; Iyer SR; Shah N; Woltjer R; Somwar R; Gilheeney SW; DeCarvalo A; Mikkelson T; Van Meir EG; Ladanyi M; Druker BJ
Clin Cancer Res; 2018 Dec; 24(24):6471-6482. PubMed ID: 30171048
[TBL] [Abstract][Full Text] [Related]
7. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract][Full Text] [Related]
8. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by
Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
[TBL] [Abstract][Full Text] [Related]
9. Discovery and functional characterization of the oncogenicity and targetability of a novel
Jain P; Iyer S; Straka J; Surrey LF; Pogoriler J; Han H; Smith T; Busch C; Fox E; Li M; Waanders AJ; Resnick A; Davare MA
Cold Spring Harb Mol Case Stud; 2022 Oct; 8(6):. PubMed ID: 36307212
[TBL] [Abstract][Full Text] [Related]
10. Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma.
Das A; Cheng RR; Hilbert ML; Dixon-Moh YN; Decandio M; Vandergrift WA; Banik NL; Lindhorst SM; Cachia D; Varma AK; Patel SJ; Giglio P
Cancer Growth Metastasis; 2015; 8():51-60. PubMed ID: 26648752
[TBL] [Abstract][Full Text] [Related]
11. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Zou HY; Li Q; Engstrom LD; West M; Appleman V; Wong KA; McTigue M; Deng YL; Liu W; Brooun A; Timofeevski S; McDonnell SR; Jiang P; Falk MD; Lappin PB; Affolter T; Nichols T; Hu W; Lam J; Johnson TW; Smeal T; Charest A; Fantin VR
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3493-8. PubMed ID: 25733882
[TBL] [Abstract][Full Text] [Related]
12. Recurrent chromosomal rearrangements of
Bayard Q; Caruso S; Couchy G; Rebouissou S; Bioulac Sage P; Balabaud C; Paradis V; Sturm N; de Muret A; Guettier C; Bonsang B; Copie C; Letouzé E; Calderaro J; Imbeaud S; Nault JC; Zucman-Rossi J
Gut; 2020 Sep; 69(9):1667-1676. PubMed ID: 31907296
[TBL] [Abstract][Full Text] [Related]
13. ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients.
Meredith DM; Cooley LD; Dubuc A; Morrissette J; Sussman RT; Nasrallah MP; Rathbun P; Yap KL; Wadhwani N; Bao L; Wolff DJ; Ida C; Sukhanova M; Horbinski C; Jennings LJ; Farooqi M; Gener M; Ginn K; Kam KL; Sasaki K; Kanagal-Shamanna R; Alexandrescu S; Brat D; Lu X
Mod Pathol; 2023 Nov; 36(11):100294. PubMed ID: 37532182
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of microRNA-133a and downregulation of connective tissue growth factor suppress cell proliferation, migration, and invasion in human glioma through the JAK/STAT signaling pathway.
Zhang P; Chen FZ; Jia QB; Hu DF
IUBMB Life; 2019 Dec; 71(12):1857-1875. PubMed ID: 31381269
[TBL] [Abstract][Full Text] [Related]
15. Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells.
Swiatek-Machado K; Mieczkowski J; Ellert-Miklaszewska A; Swierk P; Fokt I; Szymanski S; Skora S; Szeja W; Grynkiewicz G; Lesyng B; Priebe W; Kaminska B
Cancer Biol Ther; 2012 Jun; 13(8):657-70. PubMed ID: 22555804
[TBL] [Abstract][Full Text] [Related]
16. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
[TBL] [Abstract][Full Text] [Related]
17. Expression of RUNX1-JAK2 in Human Induced Pluripotent Stem Cell-Derived Hematopoietic Cells Activates the JAK-STAT and MYC Pathways.
Fortschegger K; Husa AM; Schinnerl D; Nebral K; Strehl S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299194
[TBL] [Abstract][Full Text] [Related]
18. GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors.
Richardson TE; Tang K; Vasudevaraja V; Serrano J; William CM; Mirchia K; Pierson CR; Leonard JR; AbdelBaki MS; Schieffer KM; Cottrell CE; Tovar-Spinoza Z; Comito MA; Boué DR; Jour G; Snuderl M
J Neuropathol Exp Neurol; 2019 Dec; 78(12):1089-1099. PubMed ID: 31626289
[TBL] [Abstract][Full Text] [Related]
19. Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling.
Ho JM; Beattie BK; Squire JA; Frank DA; Barber DL
Blood; 1999 Jun; 93(12):4354-64. PubMed ID: 10361134
[TBL] [Abstract][Full Text] [Related]
20. Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers.
Tao Z; Liu J; Li T; Xu H; Chen K; Zhang J; Zhou H; Sun J; Han J; Guo Z; Yang H; Cao WM; Hu X
Front Oncol; 2021; 11():741142. PubMed ID: 34650924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
